Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 February 2019, PRAC, 15/02/2019

Disclosure: This site contains some affiliate links. We might receive a small commission at no additional cost to you.

Written & Supervised By
Preventive Medicine and Public Health Specialist | 40+ Years Experience

Medically Reviewed
Dr. Jose Rossello, MD, PhD, MHCM
Preventive Medicine & Public Health Specialist
Last Reviewed: February 18, 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 February 2019 News 15/02/2019 EMA’s safety committee ( PRAC ) has started a review of the risk of QT prolongation and torsades de pointes (abnormalities of the heart’s electrical activity that may lead to heart rhythm disturbances) with fenspiride medicines. Fenspiride is used in children and adults in a number of European Union Member States to relieve cough caused by lung diseases.

Read the source article at European Medicines Agency[1]

References

  1. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 February 2019. Accessed November 4, 2025
author avatar
Jose Rossello, MD, PhD, MHCM
Dr. Rossello is a medical doctor specializing in Preventive Medicine and Public Health. He founded PreventiveMedicineDaily.com to provide evidence-based health information supported by authoritative medical research.
See Full Bio
Previous
Next
Leave a Comment

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}